Design considerations in building in silico equivalents of common experimental influenza virus assays.
about
Impact of the H275Y and I223V Mutations in the Neuraminidase of the 2009 Pandemic Influenza Virus In Vitro and Evaluating Experimental ReproducibilityA review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges aheadAvian influenza viruses that cause highly virulent infections in humans exhibit distinct replicative properties in contrast to human H1N1 viruses.The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patientsThe H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets.Exploring the effect of biological delays in kinetic models of influenza within a host or cell cultureAssessing the in vitro fitness of an oseltamivir-resistant seasonal A/H1N1 influenza strain using a mathematical modelReducing uncertainty in within-host parameter estimates of influenza infection by measuring both infectious and total viral load.(In)validating experimentally derived knowledge about influenza A defective interfering particles.How sticky should a virus be? The impact of virus binding and release on transmission fitness using influenza as an example.Exploring virus release as a bottleneck for the spread of influenza A virus infection in vitro and the implications for antiviral therapy with neuraminidase inhibitors.Accounting for Space—Quantification of Cell-To-Cell Transmission Kinetics Using Virus Dynamics Models.Influenza Virus Infection Model With Density Dependence Supports Biphasic Viral DecayHost-pathogen kinetics during influenza infection and coinfection: insights from predictive modeling
P2860
Q24288661-4744A0C0-7283-432D-89CF-7521206F1E8AQ28382972-3ABF32E5-7415-4753-94B0-825D4E5B9491Q30386911-77FE6B3C-64C2-47D4-8446-145BC4C0A778Q30397216-BD30F6D2-7939-4075-B03F-5BFE108A46F1Q30419738-DA0C0379-591C-4B3C-AC36-D3A3B24874A7Q33831147-F34387D5-3196-4818-B8D8-9AEE70A33A65Q33859412-44BF51DA-EFA9-4EF6-9B1E-382B171BF373Q34731272-9EA30995-8729-44B4-ADD9-23198905B32CQ37466028-4AFD49AE-FBCE-4A3A-81A5-8A962E1C1E53Q39271411-4BC03C96-D6F3-42A1-944A-E82D4DFAE8A3Q40072156-FDB39462-92BF-4B2D-A714-F84B791AC282Q52718267-D22AB4C7-5E50-4D53-8EE6-BA8DD9193776Q56000676-7C7F7EFD-8BCD-426F-8A11-D02330C5D852Q57232542-7BF52EFA-2E84-417C-868D-65406D8EFF9A
P2860
Design considerations in building in silico equivalents of common experimental influenza virus assays.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Design considerations in build ...... mental influenza virus assays.
@en
Design considerations in build ...... mental influenza virus assays.
@nl
type
label
Design considerations in build ...... mental influenza virus assays.
@en
Design considerations in build ...... mental influenza virus assays.
@nl
prefLabel
Design considerations in build ...... mental influenza virus assays.
@en
Design considerations in build ...... mental influenza virus assays.
@nl
P2093
P2860
P1433
P1476
Design considerations in build ...... imental influenza virus assays
@en
P2093
Benjamin P Holder
Guy Boivin
Philippe Simon
P2860
P304
P356
10.3109/08916934.2011.523267
P577
2011-01-19T00:00:00Z